At least two observations argue in favor of the in vivo relevance of our observations: (i) dectin-1 is increasingly recognized as a relevant activator of DCs (32) and (ii) altered IgG subtypes in CGD patients were identified in our study. The gene discussed is CLEC7A; the disease is chronic granulomatous disease.